Autologous stem cell transplantation for untreated transformed indolent B‐cell lymphoma in first remission: an international, multi‐centre propensity‐score‐matched study

Chin, Collin K.; Lim, Kenneth; Lewis, K.L.; Jain, Preetesh; Qing, Yun; Feng, Lei; Cheah, Chan Yoon; Seymour, John F.; Ritchie, David; Burbury, Kate; Tam, Constantine S.; Fowler, Nathan; Fayad, Luis; Westin, Jason R.; Neelapu, Sattva S.; Hagemeister, Fredrick B.; Samaniego, Felipe; Flowers, C. R.; Nastoupil, Loretta J.; Dickinson, Michael

doi:10.1111/bjh.17072

Cited by 7 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indirect treatment comparison methods have been previously used to compare treatments for hematological malignancies, with recent publications related to RRMM, acute myeloid leukemia, and B-cell lymphoma [26][27][28]. The current analysis contributed to this growing body of evidence, but this time assessing the comparative efficacy of a novel BCMA-targeted CAR-T therapy in the setting of triple-class exposed RRMM.…”

Section: Discussionmentioning

confidence: 99%

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Weisel

Martin

Krishnan³

et al. 2021

Clin Drug Investig

View full text Add to dashboard Cite

Background and Objective Ciltacabtagene autoleucel (cilta-cel) is a novel agent being investigated in the single-arm CARTI-TUDE-1 trial (NCT03548207) for patients with relapsed or refractory multiple myeloma who are triple-class exposed to an immunomodulatory drug, proteasome inhibitor, and an anti-CD38 monoclonal antibody. The objective of this study was to evaluate the comparative efficacy of cilta-cel vs physician's choice of treatment, as no head-to-head trials have been conducted. Methods An external control arm for CARTITUDE-1 was created from patients in the long-term follow-up for three clinical trials of daratumumab (POLLUX, CASTOR, and EQUULEUS) who satisfied the eligibility criteria of CARTITUDE-1. These patients received physician's choice of treatment following the discontinuation of study drugs. Inverse probability of treatment weighting was used to align the external control and CARTITUDE-1 populations on important baseline characteristics. Overall response rate, complete response or better rate, progression-free survival, time to next treatment, and overall survival were assessed. Several sensitivity analyses were conducted. Results After propensity score weighting, baseline characteristics were comparable between cohorts. Patients showed improved results with cilta-cel vs physician's choice of treatment: overall response rate (relative risk: 2.95 [95% confidence interval (CI) 2.27, 3.84; p < 0.0001]), complete response or better (relative risk: 111.70 [95% CI 29.08, 429.06; p < 0.0001]), progression-free survival (hazard ratio [HR]: 0.24 [95% CI 0.15, 0.37; p < 0.0001]), time to next treatment (HR: 0.14 [95% CI 0.09, 0.22; p < 0.0001]), and overall survival (HR: 0.21 [95% CI 0.13, 0.35; p < 0.0001]). Results were consistent across all sensitivity analyses. Conclusions Cilta-cel showed superior efficacy compared with physician's choice of treatment, making it a promising new treatment option for patients with triple-class exposed relapsed or refractory multiple myeloma.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Weisel

Martin

Krishnan³

et al. 2021

Clin Drug Investig

View full text Add to dashboard Cite

show abstract

“…Potential treatment options for patients who relapse after ASCT are novel agents such as idelalisib (a phosphoinositide 3-kinase inhibitor), obinituzumab (cluster of differentiate [CD] 20 antibody), lenalidomide (an immunomodulatory drug), venetoclax (a B-cell lymphoma-2 inhibitor), ibrutinib (a bruton tyrosine kinase inhibitor), tazemetostat (an enhancer of zeste homolog 2 inhibitor that has also shown activity in EZH wild type FL), tafasitamab (an anti-CD 19 antibody), bispecific antibodies, and chimeric antigen receptor T cells. 1 , 2 , 26 Polatuzumab vedotin (an anti-CD79 b antibody conjugated to mono-methyl auristatin), inotuzumab ozogamicin (an anti-CD 22 antibody conjugated to calicheamicin), and pidilizumab (an anti-programmed cell death protein 1 antibody) may also be options for patients who relapse after transplantation or in maintenance or bridging therapies. 3 …”

Section: Discussionmentioning

confidence: 99%

Age and lymphocyte/monocyte ratio as prognostic factors for autologous transplantation in the treatment of patients with follicular lymphoma

Kenyeres,

Kiss,

Simon

et al. 2024

J Int Med Res

View full text Add to dashboard Cite

Objective Follicular lymphoma (FL) is an indolent, lymphoproliferative disease of B-cell origin that has a heterogeneous disease course with varying outcomes. Certain patients may undergo autologous stem cell transplantation. We investigated the outcome of autologous stem cell transplantation in patients with FL. Methods Patients who received autologous stem cell transplantation at the University of Debrecen’s Department of Hematology between 2004 and 2021 were retrospectively analyzed. The overall survival (OS) and progression-free survival (PFS) after transplantation of patients with FL were examined. Prognostic factors that may influence the course of the disease were chosen. Results Data were collected from 49 patients. OS was influenced only by age, whereas PFS was affected by age and the lymphocyte/monocyte ratio. The combination of age and lymphocyte/monocyte ratio defined a patient population with a particularly unfavorable prognostic risk profile: patients over 47 years of age with a pre-transplant lymphocyte/monocyte ratio greater than or equal to 2.675. Conclusion Age and lymphocyte/monocyte ratio were identified as useful prognostic factors for PFS in patients with FL following autologous stem cell transplantation.

show abstract

“…Autologous HSCT has become a standard treatment for patients with relapsed and refractory Hodgkin lymphoma. Also, for relapsed or refractory (R/R) NHL patients, use of high dose chemotherapy (HDT) consolidation with autologous stem cell transplant (ASCT) can be curative 18 – 20 . The main mechanism is to eradicate disease activity by high-dose chemotherapy prior to PBSCT, and then supporting by stem cells infusion 21 .…”

Section: Discussionmentioning

confidence: 99%

Autologous Hematopoietic Stem Cell Transplantation for Patients with Lymphoma-Associated Hemophagocytic lymphohistiocytosis

et al. 2021

View full text Add to dashboard Cite

Background: Hemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status. Lymphoma associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. Allo-HSCT is often considered necessary. Autologous stem cell transplantation (auto-SCT) is widely used in the treatment of lymphoma, especially for high-risk NHL. There have been no clinical reports on the use of auto-SCT in LAHS in the past 20 years. Methods: We retrospectively evaluated 12 LAHS patients who received auto-SCT at our center from January 2013 to January 2020. Follow-up started at the date of LAHS diagnosis and ended at the date of death or last examination. Overall survival (OS) was calculated from the diagnosis of HLH to death of any cause. Results: The median period between diagnosis and auto-SCT is 6.7 months. All 12 patients achieved remission after transplantation. Follow-up to 1 January 2021, 8 patients remained disease-free, 4 patients relapsed and 2 of them died eventually. The median follow-up time is 20.9 months, and the median overall survival time has not been reached yet. The 3-year OS rates was 71%. Compared with LAHS patients who did not undergo transplantation during the same period (median OS time is 3.4 months), patients who underwent auto-SCT had a significantly better prognosis ( P=0.001). Even if the lymphoma reaches CR after treatment, auto-SCT still provides a better prognosis compared to CR patients without transplantation ( P=0.037). Compared with lymphoma patients without HLH who underwent auto-SCT during the same period, they had a similar prognosis ( P=0.350). Conclusion: LAHS, as a common type in secondary HLH, may have a better prognosis after removing the trigger of HLH. In this study, the autologous transplantation in LAHS can significantly improve the prognosis, and provide LAHS a similar prognosis as high-risk lymphoma without HLH.

show abstract

Autologous stem cell transplantation for untreated transformed indolent B‐cell lymphoma in first remission: an international, multi‐centre propensity‐score‐matched study

Cited by 7 publications

References 28 publications

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Age and lymphocyte/monocyte ratio as prognostic factors for autologous transplantation in the treatment of patients with follicular lymphoma

Autologous Hematopoietic Stem Cell Transplantation for Patients with Lymphoma-Associated Hemophagocytic lymphohistiocytosis

Contact Info

Product

Resources

About